Skip to content

Aspirin and Cancer

Facebook
Twitter
LinkedIn

Aspirin is often considered a wonder drug due to its versatile use in treating inflammation, reducing pain, and helping to prevent heart-related disease. However, there is more to it. Aspirin is actually cancer-preventive. Studies have shown that a daily low dose of aspirin, medically prescribed for more than five years, lowers the risk of cancer-related deaths by at least 30%. So, should we all start taking aspirin on a daily basis to lower our chances of getting cancer?

No, not exactly. This is because many aspects of aspirin’s cancer-preventive effects are still poorly understood. Particularly, researchers have not yet pinpointed what enables aspirin to selectively kill early-stage cancer cells and not healthy cells. This is the scope of the research currently being carried out at the Yeast Molecular Biology and Biotechnology Laboratory (headed by Prof. Rena Balzan).

Maria Azzopardi

The secret behind aspirin’s tendency to kill certain cells but not others seems to lie in the physiology of the exposed cells. Aspirin exploits the natural differences between healthy and cancerous cells to eliminate malignant cells before they can take over.

Oxygen, if transformed into ‘Reactive Oxygen Species’, is known to cause DNA mutations that can lead to cancer. Through this research, we studied mutated yeast cells which are a relevant model of early-stage cancer cells due to their low tolerance to oxygen-associated stress. We then identified genes in these mutant yeasts which are affected by aspirin.

One of aspirin’s targets is a key metabolite required for the production of energy-rich compounds vital for cell survival. We found that aspirin creates a shortage of this metabolite in mutated yeast cells, causing them to run out of energy and die.

This implies that early-stage human cancer cells may suffer a similar fate and, more importantly, partly explains how aspirin prevents tumour formation. Such knowledge may prove useful in the development of novel anti-cancer treatments.


This research was carried out as part of Project “R&I-2015-001”, financed by the Malta Council for Science & Technology through the R&I Technology Development Programme. This research is being carried out as part of Azzopardi’s Ph.D. project at the Centre for Molecular Medicine & Biobanking and the Department of Physiology & Biochemistry, University of Malta
  Author: Maria Azzopardi

Author

More to Explore

Guardians of the Lost Web

Digital archives safeguard our shared heritage, but in an era of cyber threats and fleeting information, who will protect these modern Libraries of Alexandria? THINK speaks to Dr Charlie Abela and Luke Brincat.

Chaotic Order: Victor Pasmore’s Abstract Art Keeps Beating

It all started with half a thousand books donated to the UM Library in 2018. Then, six years later, your columnist attended an event called Friday Talks, organised by Fondazzjoni Patrimonju Malti (FPM), the guardians of Victor Pasmore’s legacy. And like that, you, dear reader, and I – together, we fall into the rabbit hole of abstract art. From order to chaos. Down, down, down. ‘“I wonder how many miles I’ve fallen by this time?” she said aloud. “I must be getting somewhere near the centre of the earth.”’

Exploring Birżebbuġa through Soundscapes

Have you ever thought about the social implications of sounds? Daniel Gafà explored the locality of Birżebbuġa through its soundscapes. His study highlights the role that sounds play in shaping residents’ sense of place.

Comments are closed for this article!